Vmbook Online ordering

Immunocellular Therapeutics Ltd

ImmunoCellular Therapeutics, Ltd. (IMUC) is a clinical-stage company that develops immune-based therapies for the treatment of brain and other tumors. The company's lead product candidate is ICT-107, a dendritic cell-based vaccine intended for the treatment of glioblastoma, a type of brain cancer. ICT-107 has completed Phase 2 clinical trials.

ImmunoCellular Therapeutics also develops other product candidates, including ICT-121, a peptide-based vaccine targeting cancer stem cells in glioblastoma, and ICT-140, a dendritic cell-based vaccine for the treatment of various solid tumors. The company's technology platform is based on the use of dendritic cells, which are a type of immune cell that plays a key role in activating the body's immune response to cancer.

The company's stock is listed on the Nasdaq stock exchange under the ticker symbol IMUC. As of February 2021, the company's market capitalization is around 4 million USD and its stock price is around 0.2 USD. The company has not yet generated any revenue and it has been losing money since its inception.

It's important to note that investing in stocks, especially in biotech and pharmaceutical companies, can be risky and it's recommended to conduct your own research or consult with a financial advisor before making any investment decisions.

Also, the information provided here, might be slightly outdated, as the stock market is extremely dynamic and the situation can change rapidly. I encourage you to double-check the information with the latest financial news, filings and announcements from the company.